ROS1 and melanoma: Retrospective studies of spitzoid neoplasms have found activating fusions involving BRAF, RET, ROS1, ALK, or NTRK1 in 39% of melanomas with spitzoid morphology and just over 50% of Spitz nevi and atypical Spitz tumors [11, 13].